Trial Profile
Phase II trial of induction mFOLFOX6 plus Avastin followed by neoaduvant chemoradiotherapy with TS-1 for MRI-defined high-risk rectal cancer (IMPACT-RC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Rectal cancer
- Focus Therapeutic Use
- Acronyms IMPACT-RC
- 08 Jul 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Apr 2016 New trial record